First-ever bio-generic drug doesn’t help Novartis shares By: MarketWatch March 06, 2015 at 15:10 PM EST Getting the U.S. Food and Drug Administration’s first-ever approval for a biosimilar didn’t do much for Novartis shares in early trading Friday. Read More >> Related Stocks: Amgen Novartis Ag ADR